Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 332

Sort by

Sort Order Select

Journal Articles

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Chia-Yau Chang, MD, Yeu-Chin Chen, MD, Chen-Hua Tsai, MD, Jia-Ruey Tsai, MD, Yen-Lin Liu, MD, Shu-Hsia Hu

Blood (2019) 134 (Supplement_1): 2406.

https://doi.org/10.1182/blood-2019-132137

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Total Body Irradiation Free Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide for Children with Sickle Cell Disease

Satya Prakash Yadav, MBBS, DCH, DNB, Anil Sharma, MBBS, MD, Rohit Kapoor, MBBS, MD, Goutomi Chatterjee, MBBS, MD, Dhwanee Thakkar, MBBS, MDFNB, Neha Rastogi, MBBS,DCH,DNB

Blood (2019) 134 (Supplement_1): 5661.

https://doi.org/10.1182/blood-2019-130988

Published: 2019

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4252.

https://doi.org/10.1182/blood-2019-129226

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Is Hemophilia B Clinically Less Severe Than Hemophilia a? Evidence from the Hugs Va and Vb Studies

Megan M. Ullman, MA, MPH, Randall Curtis, MBA, Mimi Lou, MS, Brenda Riske, MBA, MS, Judith Baker, DrPH, MHSA, Duc Quang Tran, Jr., MD, Joanne Wu, Michael B. Nichol, PhD

Blood (2019) 134 (Supplement_1): 58.

https://doi.org/10.1182/blood-2019-129439

Published: 2019

Journal Articles

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Blood (2019) 134 (Supplement_1): 4311.

https://doi.org/10.1182/blood-2019-130062

Published: 2019

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Tomasz W. Kaminski, PharmD, Egemen Tutuncuoglu, MSc, Margaret V. Ragni, MD MPH, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 1043.

https://doi.org/10.1182/blood-2019-130471

Published: 2019

Journal Articles

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Juergen Foell, MD, Morad Morez, Anja Troeger, MD, Katharina Kleinschmidt, MD PhD, Beatrix Pfirstinger, Andreas Brosig, MD PhD, Ralph Burkhardt, MD PhD, Selim Corbacioglu, MD, Norbert Ahrens

Blood (2019) 134 (Supplement_1): 1171.

https://doi.org/10.1182/blood-2019-131984

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus

Mi-Ae Lyu, PhD, Joseph D. Khoury, MD, Mitsutaka Nishimoto, MD PhD, Ke Zeng, MD PhD, Meixian Huang, Swaminathan P. Iyer, MD, Simrit Parmar, MBBS

Blood (2019) 134 (Supplement_1): 1938.

https://doi.org/10.1182/blood-2019-131436

Published: 2019

Journal Articles

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients

Kyung Taek Hong, MD, Soyoung Lee, Jaeseong Oh, Jung Yoon Choi, MD, Hee Young Shin, MD PhD, Kyung-Sang Yu, MD PhD, Hyoung Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3594.

https://doi.org/10.1182/blood-2019-125266

Published: 2019

Journal Articles

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 3545.

https://doi.org/10.1182/blood-2019-122685

Published: 2019

Journal Articles

Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia

Hannah Le, PharmD, MPH, Trudy Pendergraft, MSPH, Svea K. Wahlstrom, VMD, MS, Kellie Ryan, MPH, Laura Sarokin, PhD, Emily Mulvihill, MBA, Thomas Campbell, PhD, Martine C. Maculaitis, PhD, Thomas W. LeBlanc, MDMA,MHS

Blood (2019) 134 (Supplement_1): 4730.

https://doi.org/10.1182/blood-2019-129606

Published: 2019

Journal Articles

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Kathrine Aarup, Lisbeth Enggaard, MD, Robert Schou Pedersen, MD PhD, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, MD Prof, Carsten Utoft Niemann, MD PhD Ass. Prof, Michael Asger Andersen, MD

Blood (2019) 134 (Supplement_1): 1767.

https://doi.org/10.1182/blood-2019-123011

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Total Body Irradiation Free Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide for Children with Sickle Cell Disease

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Is Hemophilia B Clinically Less Severe Than Hemophilia a? Evidence from the Hugs Va and Vb Studies

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Feasibility of Peripheral Blood Stem Cell Collection from Heterozygoussickle Cell Trait Donors

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia

Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Email alerts

ASH Publications

American Society of Hematology